Shares of Nektar Therapeutics (NASDAQ:NKTR), a biopharmaceutical company that utilizes its proprietary intellectual property via licensing deals and through collaborations in the clinical development process to help fight cancer, autoimmune diseases, and chronic pain, surged as much as 20% on Thursday after the company reported its fourth-quarter and full-year results after the closing bell on Wednesday.
For the quarter, Nektar wound up reporting sales of $37.5 million, a decline of 5% from the prior-year period. For the year, sales fell to $165.4 million from $230.8 million in 2015. However, it’s worth noting that Nektar received a $130 million milestone payment in 2015 from AstraZenecafollowing the first commercial sale of Movantik in the U.S. and Moventig in the European Union (EU) during the first quarter of 2015. Without this one-time milestone payment, Nektar would have demonstrated year-over-year sales growth. Both its product sales and royalty revenue increased substantially on a year-over-year basis.
free stock trading software: Benitec Biopharma Limited(BNTC)
- [By Alex McGuire]
Here’s a list of the top 10 penny stocks to watch in March, which includes the biggest gainers last month…
Penny StockCurrent Stock PriceFebruary 2017 ReturnZosano Pharma Corp. (Nasdaq: ZSAN)$2.56+123.3%Bellerophon Therapeutics Inc. (Nasdaq: BLPH)$1.25+113.8%Peregrine Pharmaceuticals (Nasdaq: PPHM)$0.59+101.7%Galectin Therapeutics Inc. (Nasdaq: GALT)$1.79+91.9%Bioanalytical Systems Inc. (Nasdaq: BASI)$1.58+90.6%CymaBay Therapeutics Inc. (Nasdaq: CBAY)$3.50+89.8%Vermillion Inc. (Nasdaq: VRML)$2.56+86.3%Naked Brand Group Inc.(Nasdaq:NAKD)$2.16+76%Eyegate Pharmaceuticals Inc. (Nasdaq: EYEG)$2.63+73.9%Benitec Biopharma Ltd. (Nasdaq ADR: BNTC)$2.60+59.9%
The best-performing penny stock – Zosano Pharma Corp. – soared an incredible 123.3% from Feb. 1 to Feb. 28. To put those gains into perspective, that’s more than five times the S&P 500’s 23% climb in the last 12 months.
- [By Lisa Levin]
Benitec Biopharma Ltd (ADR) (NASDAQ: BNTC) shares shot up 44 percent to $4.41. Benitec Biopharma disclosed that the key pre-clinical data on oculopharyngeal muscular dystrophy has been published in Nature Communications.
free stock trading software: Yahoo! Inc.(YHOO)
- [By Stark Merrifield]
That includes Yahoo! Inc. (Nasdaq: YHOO), Amazon.com Inc. (Nasdaq: AMZN), eBay Inc. (Nasdaq: EBAY), Alphabet Inc. (Nasdaq: GOOGL), and Facebook Inc. (Nasdaq: FB) – their combined market caps are worth $1.5 trillion.
- [By Jayson Derrick]
Finally, other popular names that were out of favor among TD Ameritrade's clients include Yahoo! Inc. (NASDAQ: YHOO), Chipotle Mexican Grill, Inc. (NYSE: CMG) and Alibaba Group Holding (NYSE: BABA).
- [By WWW.KIPLINGER.COM]
As much as traditional telecommunications is a poky business, VZ is making some interesting moves. Most famously it recently acquired the core properties of Yahoo! Inc. (YHOO) to drive new revenue streams and position itself for the future. And a little further back, Verizon acquired AOL.
free stock trading software: Spark Therapeutics, Inc.(ONCE)
- [By Jim Robertson]
On Wednesday, our Elite Opportunity Pronewsletter suggested going long again on small cap gene therapy stock Spark Therapeutics (NASDAQ: ONCE):
Financially, Spark Therapeutics has over $300M in cash on the books and no debt to speak of yet, which equates to a share price of just over four times cash. The Company has generated over $20M in revenue for the trailing twelve months, and although the Company is expected to continue to lose money for the next few years, any strong clinical data that hits the tape could rocket shares of ONCE overnight, just like we’ve seen with so many others over the years.
- [By Chris Lange]
Spark Therapeutics Inc. (NASDAQ: ONCE) saw its shares take a big step back on Monday after the firm reported less than favorable results at the American Society of Hematology (ASH) annual meeting. Analysts have taken this opportunity to weigh in on the stock:
- [By Paul Ausick]
Spark Therapeutics Inc. (NASDAQ: ONCE) dropped 44% Monday to post a new 52-week low of $41.06 after closing at $73.38 on Friday. The 52-week high is $91.75. Volume was around 13.5 million, nearly 30 times the daily average of about 480,000. The company’s hemophilia A drug posted disappointing trial results.
free stock trading software: Orocobre Limited (OROCF)
- [By SEEKINGALPHA.COM]
The question now is more about speed of EV implementation. On the supply side, it has been great to see LAC, Pilbara Minerals (OTCPK:PILBF) and Altura Mining (OTCPK:ALTAF) get funding, but the continued issues with Albemarle’s (NYSE:ALB) LaNegra II expansion and Orocobre (OTCPK:OROCF) ramping up to Phase 1 capacity of 17,500 tonnes/year of lithium carbonate are further evidence that lithium projects take time and have considerable execution risk.
- [By SEEKINGALPHA.COM]
The other producing lithium miners, and soon to be producers. I have discussed these previously in detail here, here and here. Needless to say, the top 3 producers are non-pure plays (SQM (NYSE:SQM), Albemarle (NYSE:ALB), and FMC Corp. (NYSE:FMC)). The top pure play currently producing miners are Orocobre (ASX:ORE) (OTCPK:OROCF), Tianqi Lithium (SHE:002466), Jiangxi Ganfeng Lithium, Galaxy Resources, Mineral Resources [ASX:MIN] (OTC:MALRF), and Neometals [ASX:NMT] (OTC:RRSSF). The near-term producers include Altura Mining [ASX:AJM] (OTCPK:ALTAF), Pilbara Minerals (ASX:PLS) (OTC:PILBF), Kidman Resources (ASX:KDR), Critical Elements, Nemaska Lithium (OTCQX:NMKEF) [TSX:NMX], Lithium Americas (OTCQX:LACDF) [TSX:LAC], Lithium X (OTCQX:LIXXF) (TSXV:LIX), Neo Lithium, and Bacanora Minerals (OTC:BCRMF) [TSXV:BCN], Advantage Lithium (OTCQB:AVLIF) [AAL], European Metals (OTCPK:MNTCF, ASX:EMH, AIM:EMH) and Pure Energy (OTCQB:PEMIF) [PE].